Strong Dollar Does Have Drag on Earnings, CEO Says

The transcript discusses Sandoz's positive quarterly results, driven by healthcare normalization and new launches. It addresses inflation's impact on generics, strategic options for Sandoz, and the effects of dollar strength on business strategy. The focus remains on long-term R&D despite potential recession, emphasizing the countercyclical nature of pharmaceuticals.

How does the strengthening dollar affect the company's sales and earnings?

In what ways does the company plan to balance its sales base between US and international markets?

What is the company's perspective on R&D investment in light of potential economic downturns?